drugset / Trial / NCT01523860

Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma

NCT01523860

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a brief chemoimmunotherapy with the combination of Rituximab + Bendamustine + Mitoxantrone in elderly patients with advanced stage Follicular Lymphoma.

Timeline

Start
2009-06
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bendamustine Small molecule 90 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 8 mg/m2 Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications